In PCPs the mechanism by which BRAFV600E mutation is oncogenic has not yet been fully understood but it may give both a proliferative advantage to tumor SOX2+ stem cells and impair their differentiation potential (1, 15, 16). This evidence concerns the gene SOX2 and neoplasm.